Skip to main content
TipRanks
Go Ultimate75% OFF

Revive Therapeutics (RVVTF) AI Stock Analysis

58 Followers
RVVTF

Revive Therapeutics

(Other OTC:RVVTF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low Debt BurdenVery low debt, including zero reported total debt in 2026, limits near-term refinancing pressure and interest obligations. This provides some financial flexibility while Revive advances its drug-development programs, although the benefit is constrained by the company’s negative equity and limited asset base.
Negative Factors
No Commercial RevenueThe absence of reported revenue shows that Revive remains in a development-stage model without commercial sales supporting operations. Until a drug candidate reaches a revenue-generating stage, progress depends on clinical and regulatory execution rather than an established commercial base, increasing business uncertainty.

Revive Therapeutics (RVVTF) vs. SPDR S&P 500 ETF (SPY)

-100%0%100%200%300%400%500%RVVTF0.00%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$6.67M
Dividend Yield
―
Average Volume (3M)
176.51K
Price to Earnings (P/E)
-12.5
Beta (1Y)
-1.72
Revenue Growth
―
EPS Growth
91.01%
Country
US
Employees
2
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Revive Therapeutics Business Overview & Revenue Model

Company Description

Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory...

Revive Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

RVVTF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:RAMMTSE:RAMM42NeutralCAD 1.19M-0.13-194.41%―-66.40%31.38%
TSE:PCLOTSE:PCLO39UnderperformCAD 8.41M-2.4128.59%―0.90%57.73%

* Healthcare Sector Average

Performance Comparison

0%200%400%RVVTFTSE:PCLOTSE:RAMMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RVVTF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RVVTFRevive Therapeutics0.010.000.00%
TSE:PCLOPharmacielo0.040.000.00%
TSE:RAMMRamm Pharma Corp0.01-0.05-83.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.